Enzymological and pharmacological profile of T-0156, a potent and selective phosphodiesterase type 5 inhibitor

European Journal of Pharmacology

Volumn 456, Issue 1-3, 2002, Pages 91-98

  Mochida, Hideki ^a   Takagi, Michino ^a   Inoue, Hirotaka ^a   Noto, Tsunehisa ^a   Yano, Koji ^a   Fujishige, Kotomi ^a   Sasaki, Takashi ^a   Yuasa, Keizo ^a   Kotera, Jun ^a   Omori, Kenji ^a   Kikkawa, Kohei ^a  

^a MITSUBISHI TANABE PHARMA CORPORATION   (Japan)

Author keywords

Corpus cavernosum; Cyclic guanosine monophosphate; Phosphodiesterase isozyme; Phosphodiesterase type 5 inhibitor; T 0156; Tumescence

Indexed keywords

2 (2 METHYLPYRIDIN 4 YL)METHYL 4 (3,4,5 TRIMETHOXYPHENYL) 8 (PYRIMIDIN 2 YL)METHOXY 1,2 DIHYDRO 1 OXO 2,7 NAPHTHYRIDINE 3 CARBOXYLIC ACID METHYL ESTER; CYCLIC GMP; ISOENZYME; NITRIC OXIDE; PHOSPHODIESTERASE; PHOSPHODIESTERASE 2; PHOSPHODIESTERASE I; PHOSPHODIESTERASE III; PHOSPHODIESTERASE INHIBITOR; PHOSPHODIESTERASE IV; PHOSPHODIESTERASE TYPE 6; PHOSPHODIESTERASE V; SILDENAFIL; T 0156; UNCLASSIFIED DRUG; CGMP BINDING, CGMP SPECIFIC 3',5' CYCLIC NUCLEOTIDE PHOSPHODIESTERASE; CGMP-BINDING, CGMP-SPECIFIC 3',5'-CYCLIC NUCLEOTIDE PHOSPHODIESTERASE; CYCLIC GMP PHOSPHODIESTERASE; NAPHTHYRIDINE DERIVATIVE; PYRIMIDINE DERIVATIVE; T0156;

ANIMAL TISSUE; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CORPUS CAVERNOSUM; DOG; DRUG EFFECT; DRUG POTENCY; DRUG SELECTIVITY; ELECTRIC FIELD; ELECTROSTIMULATION; ENZYME INHIBITION; ENZYME ISOLATION; HYDROLYSIS; IC 50; IN VITRO STUDY; IN VIVO STUDY; MALE; MUSCLE RELAXATION; NERVE STIMULATION; NONHUMAN; PELVIC NERVE; PRIORITY JOURNAL; RABBIT; ANESTHESIA; ANIMAL; BINDING COMPETITION; DOSE RESPONSE; KINETICS; METABOLISM; MUSCLE CONTRACTION; PENIS; PENIS ERECTION; PHYSIOLOGY; RADIOASSAY;

3',5'-CYCLIC-GMP PHOSPHODIESTERASE; ANESTHESIA; ANIMALS; BINDING, COMPETITIVE; CYCLIC GMP; DOGS; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTRIC STIMULATION; ISOENZYMES; KINETICS; MALE; MUSCLE CONTRACTION; NAPHTHYRIDINES; PENILE ERECTION; PENIS; PHOSPHODIESTERASE INHIBITORS; PHOSPHORIC DIESTER HYDROLASES; PYRIMIDINES; RABBITS; RADIOLIGAND ASSAY;

EID: 0037027933     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(02)02590-6     Document Type: Article

References (25)

1. Ahn H.S., Crim W., Romano M., Sybertz E., Pitts B. Effects of selective inhibitors on cyclic nucleotide phosphodiesterases of rabbit aorta. Biochem. Pharmacol. 38:1989;3331-3339.
2. Ballard S.A., Gingell C.J., Tang K., Turner L.A., Price M.E., Naylor A.M. Effects of sildenafil on the relaxation of human corpus cavernosum tissue in vitro and on the activities of cyclic nucleotide phosphodiesterase isozymes. J. Urol. 159:1998;2164-2171.
3. Beavo J.A. Cyclic nucleotide phosphodiesterases: functional implications of multiple isoforms. Physiol. Rev. 75:1995;725-748.
4. Beavo J.A., Reifsnyder D.H. Primary sequence of cyclic nucleotide phosphodiesterase isozymes and the design of selective inhibitors. Trends Pharmacol. Sci. 11:1990;150-155.
5. Boolell M., Allen M.J., Ballard S.A., Gepi-Attee S., Muirhead G.J., Naylor A.M., Osterloh I.H., Gingell C. Sildenafil: an orally active type 5 cyclic GMP-specific phosphodiesterase inhibitor for the treatment of penile erectile dysfunction. Int. J. Impot. Res. 8:1996;47-52.
6. Coquil J.F., Brunelle G., Guedon J. Occurrence of the methylisobutylxanthine-stimulated cyclic GMP binding protein in various rat tissues. Biochem. Biophys. Res. Commun. 127:1985;226-231.
7. Fawcett L., Baxendale R., Stacey P., McGrouther C., Harrow I., Soderling S., Hetman J., Beavo J.A., Phillips S.C. Molecular cloning and characterization of a distinct human phosphodiesterase gene family: PDE11A. Proc. Natl. Acad. Sci. U. S. A. 197:2000;3702-3707.
8. Goldstein I., Lue T.F., Padma-Nathan H., Rosen R.C., Steers W.D., Wicker P.A. Oral sildenafil in the treatment of erectile dysfunction. Sildenafil Study Group. N. Engl. J. Med. 338:1998;1397-1404.
9. Hartell N.A. Inhibition of cGMP breakdown promotes the induction of cerebellar long-term depression. J. Neurosci. 16:1996;2881-2890.
10. Jeremy J.Y., Ballard S.A., Naylor A.M., Miller M.A., Angelini G.D. Effects of sildenafil, a type-5 cGMP phosphodiesterase inhibitor, and papaverine on cyclic GMP and cyclic AMP levels in the rabbit corpus cavernosum in vitro. Br. J. Urol. 79:1997;958-963.
11. Kikkawa K., Noto T., Yano K., Inoue H., Mochida H., Takagi M. Pharmacological profile of T-0156, a newly synthesized phosphodiesterase type 5 inhibitor, in anesthetized dogs. Jpn. J. Pharmacol. 85:2001;282P.
12. Kotera J., Fujishige K., Michibata H., Yuasa K., Kubo A., Nakamura Y., Omori K. Characterization and effects of methyl-2-(4-aminophenyl)-1, 2-dihydro-1-oxo-7-(2-pyridinylmethoxy)-4-(3,4, 5-trimethoxyphenyl)-3-isoquinoline carboxylate sulfate (T-1032), a novel potent inhibitor of cGMP-binding cGMP-specific phosphodiesterase (PDE5). Biochem. Pharmacol. 60:2000;1333-1341.
13. Lincoln T.M., Hall C.L., Park C.R., Corbin J.D. Guanosine 3′:5′-cyclic monophosphate binding proteins in rat tissues. Proc. Natl. Acad. Sci. U. S. A. 73:1976;2559-2563.
14. Noto T., Inoue H., Ikeo T., Kikkawa K. Potentiation of penile tumescence by T-1032, a new potent and specific phosphodiesterase type V inhibitor, in dogs. J. Pharmacol. Exp. Ther. 294:2000;870-875.
15. Soderling S.H., Bayuga S.J., Beavo J.A. Cloning and characterization of a cAMP-specific cyclic nucleotide phosphodiesterase. Proc. Natl. Acad. Sci. U. S. A. 95:1998;8991-8996.
16. Soderling S.H., Bayuga S.J., Beavo J.A. Identification and characterization of a novel family of cyclic nucleotide phosphodiesterases. J. Biol. Chem. 273:1998;15553-15558.
17. Soderling S.H., Bayuga S.J., Beavo J.A. Isolation and characterization of a dual-substrate phosphodiesterase gene family: PDE10A. Proc. Natl. Acad. Sci. U. S. A. 95:1999;7071-7076.
18. Souness J.E., Brazdil R., Diocee B.K., Jordan R. Role of selective cyclic GMP phosphodiesterase inhibition in the myorelaxant actions of M and B 22,948, MY-5445, vinpocetine and 1-methyl-3-isobutyl-8-(methylamino)xanthine. Br. J. Pharmacol. 98:1989;725-734.
19. Takagi M., Mochida H., Noto T., Yano K., Inoue H., Ikeo T., Kikkawa K. Pharmacological profile of T-1032, a novel specific phosphodiesterase type 5 inhibitor, in isolated rat aorta and rabbit corpus cavernosum. Eur. J. Pharmacol. 411:2001;161-168.
20. Thompson W.J., Terasaki W.L., Epstein P.M., Strada S.J. Assay of cyclic nucleotide phosphodiesterase and resolution of multiple molecular forms of the enzyme. Adv. Cycl. Nucleotide Res. 10:1979;69-92.
21. Trigo-Rocha F., Hsu G.L., Donatucci C.F., Lue T.F. The role of cyclic adenosine monophosphate, cyclic guanosine monophosphate, endothelium and nonadrenergic, noncholinergic neurotransmission in canine penile erection. J. Urol. 149:1993;872-877.
22. Trigo-Rocha F., Aronson W.J., Hohenfellner M., Ignarro L.J., Rajfer J., Lue T.F. Nitric oxide and cGMP: mediators of pelvic nerve-stimulated erection in dogs. Am. J. Physiol. 264:1993;H419-H422.
23. Turko I.V., Francis S.H., Corbin J.D. Potential roles of conserved amino acids in the catalytic domain of the cGMP-binding cGMP-specific phosphodiesterase. J. Biol. Chem. 273:1998;6460-6466.
24. Turko I.V., Ballard S.A., Francis S.H., Corbin J.D. Inhibition of cyclic GMP-binding cyclic GMP-specific phosphodiesterase (Type 5) by sildenafil and related compounds. Mol. Pharmacol. 56:1999;124-130.
25. Wallis R.M., Corbin J.D., Francis S.H., Ellis P. Tissue distribution of phosphodiesterase families and the effects of sildenafil on tissue cyclic nucleotides, platelet function, and the contractile responses of trabeculae carneae and aortic rings in vitro. Am. J. Cardiol. 83:1999;3C-12C.